JP7417530B2 - 優先投与される免疫増強薬 - Google Patents

優先投与される免疫増強薬 Download PDF

Info

Publication number
JP7417530B2
JP7417530B2 JP2020547008A JP2020547008A JP7417530B2 JP 7417530 B2 JP7417530 B2 JP 7417530B2 JP 2020547008 A JP2020547008 A JP 2020547008A JP 2020547008 A JP2020547008 A JP 2020547008A JP 7417530 B2 JP7417530 B2 JP 7417530B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
optionally substituted
compound
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020547008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515775A (ja
JP2021515775A5 (OSRAM
Inventor
カルロス ハエン フアン
リー ジェフリー ジェナ
ジン リクシア
カリシーク ヤロスロウ
ブイ．ローソン ケネス
レディ レレティ マンモハン
ジェイ．カラクンネル エム．ディー．ジョイソン
パトリック パワーズ ジェイ
Original Assignee
アーカス バイオサイエンシズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシズ インコーポレイティド filed Critical アーカス バイオサイエンシズ インコーポレイティド
Publication of JP2021515775A publication Critical patent/JP2021515775A/ja
Publication of JP2021515775A5 publication Critical patent/JP2021515775A5/ja
Priority to JP2023170366A priority Critical patent/JP2023165998A/ja
Application granted granted Critical
Publication of JP7417530B2 publication Critical patent/JP7417530B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020547008A 2018-03-09 2019-03-08 優先投与される免疫増強薬 Active JP7417530B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023170366A JP2023165998A (ja) 2018-03-09 2023-09-29 優先投与される免疫増強薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862641003P 2018-03-09 2018-03-09
US62/641,003 2018-03-09
US201862700548P 2018-07-19 2018-07-19
US62/700,548 2018-07-19
PCT/US2019/021300 WO2019173682A1 (en) 2018-03-09 2019-03-08 Parenterally administered immune enhancing drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023170366A Division JP2023165998A (ja) 2018-03-09 2023-09-29 優先投与される免疫増強薬

Publications (3)

Publication Number Publication Date
JP2021515775A JP2021515775A (ja) 2021-06-24
JP2021515775A5 JP2021515775A5 (OSRAM) 2022-03-16
JP7417530B2 true JP7417530B2 (ja) 2024-01-18

Family

ID=67846288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020547008A Active JP7417530B2 (ja) 2018-03-09 2019-03-08 優先投与される免疫増強薬
JP2023170366A Withdrawn JP2023165998A (ja) 2018-03-09 2023-09-29 優先投与される免疫増強薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023170366A Withdrawn JP2023165998A (ja) 2018-03-09 2023-09-29 優先投与される免疫増強薬

Country Status (8)

Country Link
US (1) US12433836B2 (OSRAM)
EP (1) EP3761993A4 (OSRAM)
JP (2) JP7417530B2 (OSRAM)
KR (1) KR102822181B1 (OSRAM)
CN (1) CN112004541A (OSRAM)
AU (1) AU2019231781B2 (OSRAM)
CA (1) CA3092585A1 (OSRAM)
WO (1) WO2019173682A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201805506YA (en) 2016-01-08 2018-07-30 Arcus Biosciences Inc Modulators of 5'-nucleotidase, ecto and the use thereof
US11530234B2 (en) 2018-09-11 2022-12-20 Risen (Suzhou) Pharma Tech Co., Ltd. CD73 inhibitors and pharmaceutical uses thereof
EP3849992A4 (en) * 2018-09-11 2022-06-29 Risen (Suzhou) Pharma Tech Co., Ltd. Cd73 inhibitors and pharmaceutical uses thereof
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
WO2020185859A1 (en) 2019-03-12 2020-09-17 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
EP3947463A4 (en) 2019-03-29 2022-12-21 Arcus Biosciences, Inc. TREATMENT OF CANCER USING AN IDENTIFIED ADENOSINE FINGERPRINT
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑，其製備方法和應用
TW202131932A (zh) * 2019-11-05 2021-09-01 美商博奥阿迪斯有限公司 作為cd73抑制劑的化合物
US20230086099A1 (en) * 2020-01-30 2023-03-23 Ona Therapeutics, S.L. Combination therapy for treatment of cancer and cancer metastasis
TWI874791B (zh) 2020-02-18 2025-03-01 美商基利科學股份有限公司 抗病毒化合物
AU2021224588B2 (en) 2020-02-18 2024-07-18 Gilead Sciences, Inc. Antiviral compounds
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
AU2021292195A1 (en) 2020-06-17 2023-01-05 Arcus Biosciences, Inc. Crystalline forms of a CD73 inhibitor and uses thereof
JP7688152B2 (ja) 2021-04-16 2025-06-03 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
TW202308657A (zh) * 2021-05-11 2023-03-01 大陸商四川海思科製藥有限公司 小分子cd73拮抗劑及其用途
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ， インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法
WO2023076392A1 (en) 2021-10-26 2023-05-04 Southern Research Institute Development of novel clofarabine analogs for cancer therapy
CN119365476A (zh) * 2022-06-17 2025-01-24 上海森辉医药有限公司 一种环戊基腺苷衍生物及其药物用途
CN120091809A (zh) * 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂
CN117924394A (zh) * 2023-09-05 2024-04-26 厦门大学 核苷酸类化合物及其制备方法和应用、核素靶向探针及其制备方法和应用、药物组合物
CN117562915A (zh) * 2023-12-05 2024-02-20 中国药科大学 一种腺苷衍生物在制备预防、缓解或治疗纤维化疾病的药物中的应用
CN120285176A (zh) * 2025-04-25 2025-07-11 谈高 抗CD73单抗联合Adora1抑制剂在治疗肠纤维化中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535038A (ja) 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
US20170267710A1 (en) 2016-01-08 2017-09-21 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5569650A (en) * 1993-06-11 1996-10-29 Sloan-Kettering Institute For Cancer Research C-nucleoside isosters of analogs thereof and pharmaceutical compositions
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
EP3518934A4 (en) * 2016-10-03 2020-06-24 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
JP7150712B2 (ja) 2016-11-18 2022-10-11 アーカス バイオサイエンシズ インコーポレイティド Ｃｄ７３媒介免疫抑制の阻害剤
EP3893891A4 (en) * 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003535038A (ja) 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
JP2017513955A (ja) 2014-04-25 2017-06-01 ビテ・ファーマシューティカルズ・インコーポレイテッドＶｉｔａｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療用のｃｄ７３阻害剤としてのプリン誘導体
US20170267710A1 (en) 2016-01-08 2017-09-21 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof

Also Published As

Publication number Publication date
CN112004541A (zh) 2020-11-27
KR102822181B1 (ko) 2025-06-18
AU2019231781A1 (en) 2020-10-22
US20200405629A1 (en) 2020-12-31
EP3761993A4 (en) 2022-03-09
WO2019173682A1 (en) 2019-09-12
US12433836B2 (en) 2025-10-07
AU2019231781B2 (en) 2025-02-13
JP2021515775A (ja) 2021-06-24
CA3092585A1 (en) 2019-09-12
JP2023165998A (ja) 2023-11-17
KR20200130843A (ko) 2020-11-20
EP3761993A1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
KR102822181B1 (ko) 비경구적으로 투여된 면역 향상 약물
JP7698677B2 (ja) ５’ヌクレオチダーゼ，エクトのモジュレーター及びその使用
TWI781960B (zh) 腺核苷5'-核苷酸酶之抑制劑及相關用途
TW201822772A (zh) Cd-73介導免疫抑制之抑制劑
US20210002306A1 (en) Arginase inhibitors
HK40043095A (en) Parenterally administered immune enhancing drugs
HK40106303A (en) Modulators of 5'-nucleotidase, ecto and the use thereof
HK40073403A (zh) 胞外5’-核苷酸酶的调节剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220308

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220308

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221216

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20231109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240105

R150 Certificate of patent or registration of utility model

Ref document number: 7417530

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150